Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 39-11 / BIG 4-11 (APHINITY) 

A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

DESIGN

please click on the picture to see a larger version

Study Chairs:
Prof. Dr. med. Gunter von Minckwitz - Düsseldorf, Germany
Jose Baselga, MD, PhD - Boston, MA
José Bines, MD - Rio de Janeiro, Brazil


IBCSG Study Chair:
Prof. Guy Jéruslem, Liège, Belgium

Statisticians:
Ian Bradbury, PhD - Kincraig, Scotland

Lead Trial Coordinator:
Holly Shaw

Trial Monitor
Giuseppe Achille
IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: aphinity-monitoring@ibcsg.org

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg39_aphinity@fstrf.org

Date of Activation:
October 4, 2011

Targeted Accrual:
3806 patients

Final Accrual:
4805 patients

Date of Closure:
August 31, 2013

 



News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print